SUPPORTING INFORMATION

Preparation of Benzylphosphonates via a Palladium(0)-Catalyzed Cross-coupling of H-Phosphonate Diesters with Benzyl Halides. Synthetic and Mechanistic Studies

Gaston Lavén, Marcin Kalek, Martina Jezowska, and Jacek Stawinski*

Purification of benzylphosphonates 1-13: Silica gel chromatography, using **A.** pentane : EtOAc 1:1 \rightarrow 0:1 or **B.** CH₂Cl₂:MeOH 10:0 \rightarrow 9:1; or extraction **C.** Residue was partitioned between EtOAc (50 mL) and aq. 1 M NaOH (50 mL) and the organic phase extracted twice with aq. 1 M NaOH (2×50 mL). Combined aqueous layers were acidified with 6 M HCl, and extracted 3 times with CH₂Cl₂ (3×50 mL). The combined organic layers were washed with water, dried with Na₂SO₄, and evaporated. Purity of the isolated compounds >98% (¹H NMR spectroscopy)

Diethyl benzylphosphonate (1). Purified with **A**; yellow oil, 203 mg yield (89 %). ¹H NMR (400 MHz, CDCl3): δ 7.34-7.25 (m, 5H), 4.03 (m, 4H), 3.17 (d, J = 21.5Hz, 2H), 1.26 (t, J = 7.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 131.8 (d, ² $J_{P-C} = 8.8$ Hz), 129.9 (d, ³ $J_{P-C} = 6.7$ Hz), 128.7 (d, ⁴ $J_{P-C} = 2.9$ Hz), 127.0 (d, ⁵ $J_{P-C} = 3.7$ Hz), 62.3 (d, ² $J_{P-C} = 6.6$ Hz), 33.9 (d, ¹ $J_{P-C} = 137.9$ Hz), 16.5 (d, ³ $J_{P-C} = 6.2$ Hz); ³¹P NMR (162 MHz, CDCl₃): δ 26.4; HRMS: m/z 251.0818 ([M+Na]⁺, C₁₁H₁₇NaO₃P⁺ calcd. 251.0808).

Diethyl (4-methylbenzyl)phosphonate (2). Purified with **A**; yellow oil, 233 mg yield (88 %). ¹H NMR (400 MHz, CDCl3): δ 7.20-7.09 (m, 4H), 4.01 (m, 4H), 3.11 (d, J = 21.4 Hz, 2H), 2.32 (d, J = 2.3 Hz, 3H), 1.24 (t, J = 7.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 136.5 (d, J_{P-C} = 3.7 Hz), 129.7 (d, J_{P-C} = 6.6 Hz), 129.3 (d, J_{P-C} = 3.1 Hz),

128.5 (d, $J_{P-C} = 9.0$ Hz), 62.1 (d, $J_{P-C} = 6.7$ Hz), 33.4 (d, $J_{P-C} = 138.5$ Hz), 21.2, 16.5 (d, $J_{P-C} = 6.0$ Hz); ³¹P NMR (162 MHz, CDCl₃): δ 26.7; HRMS: m/z 265.0975 ([M+Na]⁺, C₁₁H₁₇NaO₃P⁺ calcd. 265.0964).

Diethyl (4-methoxybenzyl)phosphonate (3). Purified with **A**; yellow oil, 225 mg yield (87 %). ¹H NMR (400 MHz, CDCl3): δ 7.21 (m, 2H), 6.84 (m, 2H), 4.03 (m, 4H), 3.79 (s, 3H), 3.08 (d, J = 21.6 Hz, 2H), 1.24 (t, J = 7.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 158.7 (d, $J_{P-C} = 3.6$ Hz), 130.8 (d, $J_{P-C} = 6.5$ Hz), 123.5 (d, $J_{P-C} = 9.2$ Hz), 114.1 (d, $J_{P-C} = 3.0$ Hz), 62.2 (d, $J_{P-C} = 6.6$ Hz), 55.3, 32.9 (d, $J_{P-C} = 139.5$ Hz), 16.5 (d, $J_{P-C} = 6.0$ Hz); ³¹P NMR (162 MHz, CDCl₃): δ 26.8; HRMS: m/z 281.0925 ([M+Na]⁺, C₁₂H₁₉NaO₄P⁺ calcd. 281.0913).

Diethyl (4-fluorobenzyl)phosphonate (4). Purified with **A**; yellow oil, 236 mg yield (96 %). ¹H NMR (400 MHz, CDCl3): δ 7.28 (m, 2H), 7.02 (m, 2H), 4.03 (m, 4H), 3.12 (d, J = 21.4 Hz, 2H), 1.26 (t, J = 7.1 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 161.9 (dd, ⁵ $J_{P-C} = 4.8$ Hz, ¹ $J_{F-C} = 245.4$ Hz), 131.2 (dd, ³ $J_{P-C} = 6.6$ Hz, ³ $J_{F-C} = 8.1$ Hz), 127.4 (dd, ² $J_{P-C} = 9.0$ Hz, ⁴ $J_{F-C} = 3.4$ Hz), 115.4 (dd, ⁴ $J_{P-C} = 3.0$ Hz, ² $J_{F-C} = 21.5$ Hz), 62.1 (d, ² $J_{P-C} = 6.6$ Hz), 32.9 (d, ¹ $J_{P-C} = 139.4$ Hz), 16.4 (d, ³ $J_{P-C} = 6.0$ Hz). ³¹P NMR (162 MHz, CDCl₃): δ 26.1 (d, ⁶ $J_{P-F} = 5.9$ Hz); HRMS: *m*/*z* 269.0727 ([M+Na]⁺, C₁₁H₁₆FNaO₃P⁺ calcd. 269.0713);

Diethyl (4-chlorobenzyl)phosphonate (5). Purified with **A**; yellow oil, 234 mg yield (90 %). ¹H NMR (400 MHz, CDCl3): δ 7.31-7.21 (m, 4H), 4.07-3.97 (m, 4H), 3.11 (d, J = 21.7 Hz), 1.25 (t, J = 7.1 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 133.1 (d, ⁵ $J_{P-C} = 4.1$ Hz), 131.3 (d, ³ $J_{P-C} = 6.7$ Hz), 130.5 (d, ² $J_{P-C} = 9.1$ Hz), 128.9 (d, ⁴ $J_{P-C} = 3.1$ Hz), 62.4 (d, ² $J_{P-C} = 6.8$ Hz), 33.4 (d, ¹ $J_{P-C} = 138.7$ Hz), 16.6 (d, ³ $J_{P-C} = 5.9$ Hz); ³¹P NMR (162 MHz, CDCl₃): δ 25.7; HRMS: m/z 285.0418 ([M+Na]⁺, C₁₁H₁₆FNaO₃P⁺ calcd. 285.0418);

Diethyl (4-bromobenzyl)phosphonate (6). Purified with **A**; yellow oil, 249 mg yield (86 %). ¹H NMR (400 MHz, CDCl3): δ 7.45-7.40 (m, 2H), 7.19-7.14 (m, 2H), 4.06-

3.97 (m, 4H), 3.08 (d, J = 21.7 Hz, 2H), 1.24 (t, J = 7.1 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 131.8 (d, ⁴ $J_{P-C} = 3.1$ Hz), 131.6 (d, ³ $J_{P-C} = 6.6$ Hz), 131.0 (d, ² $J_{P-C} = 9.1$ Hz), 121.1 (d, ⁵ $J_{P-C} = 4.7$ Hz), 62.3 (d, ² $J_{P-C} = 6.8$ Hz), 33.4 (d, ¹ $J_{P-C} = 138.6$ Hz), 16.5 (d, ³ $J_{P-C} = 6.1$ Hz); ³¹P NMR (162 MHz, CDCl₃): δ 25.4; HRMS: m/z 328.9915 ([M+Na]⁺, C₁₁H₁₆FNaO₃P⁺ calcd. 328.9913);

Diethyl (4-vinylbenzyl)phosphonate (7). Purified with A; colorless oil, 207 mg yield (92 %). ¹H NMR (400 MHz, CDCl3): δ 7.37-7.33 (m, 2H), 7.27-7.24 (m, 2H), 6.69 (dd, J = 17.6 Hz, 10.8 Hz, 1H), 5.72 (d, J = 17.6 Hz, 1H), 5.22 (d, J = 10.8 Hz, 1H), 4.06-3.96 (m, 4H), 3.14 (d, J = 21.8 Hz, 2H), 1.24 (t, J = 7.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 136.5 (d, ⁶ $J_{P-C} = 2.0$ Hz), 136.3 (d, ⁵ $J_{P-C} = 3.9$ Hz), 131.3 (d, ² $J_{P-C} = 9.5$ Hz), 130.0 (d, ³ $J_{P-C} = 6.6$ Hz), 126.5 (d, ⁴ $J_{P-C} = 3.2$ Hz), 113.8 (d, ⁷ $J_{P-C} = 1.5$ Hz), 62.2 (d, ² $J_{P-C} = 6.7$ Hz), 33.7 (d, ¹ $J_{P-C} = 138.3$ Hz), 16.7 (d, ³ $J_{P-C} = 6.1$ Hz); ³¹P NMR (162 MHz, CDCl₃): δ 26.2; HRMS: m/z 277.0944 ([M+Na]⁺, C₁₂H₁₉NaO₆P⁺ calcd. 277.0964);

Diethyl (3-pyridylmethyl)phosphonate (8). Purified with **A**; yellow oil, 217 mg yield (92 %). ¹H NMR (400 MHz, CDCl3): δ 8.51-8.47 (m, 2H), 7.66 (m, 1H), 7.24 (m, 1H), 4.07-4.03 (m, 4H), 3.11 (d, J = 21.7 Hz, 2H), 1.24 (t, J = 7.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 150.7 (d, ³ $J_{P-C} = 7.5$ Hz), 148.4 (d, ⁵ $J_{P-C} = 3.7$ Hz), 137.2 (d, ³ $J_{P-C} = 5.8$ Hz), 128.0 (d, ² $J_{P-C} = 9.1$ Hz), 123.5 (d, ⁴ $J_{P-C} = 2.9$ Hz), 62.4 (d, ² $J_{P-C} = 6.9$ Hz), 31.1 (d, ¹ $J_{P-C} = 139.6$ Hz), 16.5 (d, ³ $J_{P-C} = 5.9$ Hz); ³¹P NMR (162 MHz, CDCl₃): δ 25.1; HRMS: m/z 252.0751 ([M+Na]⁺, C₁₀H₁₆NNaO₃P⁺ calcd. 252.0760);

Diethyl (4-carboxybenzyl)phosphonate (9). Purified with **C**; white solid, 271 mg yield (99 %). ¹H NMR (400 MHz, CDCl3): δ 8.03 (d, H_{Ar}, J = 8.0 Hz, 2H), 7.40 (dd, H_{Ar}, J = 8.3, 2.4 Hz, 2H), 4.12-4.02 (m, 4H), 3.26 (d, J_{P-C} = 22.3 Hz, 2H), 1.27 (t, J = 7.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 170.5, 137.6 (² J_{P-C} = 9.3 Hz), 130.5 (⁴ J_{P-C})

$$_{\rm C}$$
 = 3.0 Hz), 130.0 (${}^{3}J_{\rm P-C}$ = 6.5 Hz), 128.7 (${}^{5}J_{\rm P-C}$ = 3.6 Hz), 62.7 (${}^{2}J_{\rm P-C}$ = 6.9 Hz), 34.1 (${}^{1}J_{\rm P-C}$ = 137.8 Hz), 16.5 (${}^{3}J_{\rm P-C}$ = 6.0 Hz);

³¹P NMR (162 MHz, CDCl₃): δ 25.6; HRMS: *m/z* 295.0689 ([M+Na]⁺, C₁₁H₁₆FNaO₃P⁺ calcd. 295.0706);

Ethyl 5-diethylphosphonomethylfuran-2-carboxylate (10). Purified with A; yellow oil, 262 mg yield (99 %). ¹H NMR (400 MHz, CDCl3): δ 7.10 (d, J = 3.4 Hz, 1H), 6.39 (dd, J = 3.8, 3.4 Hz, 1H), 4.33 (q, J = 7.2 Hz, 2H), 4.15-4.06 (m, 4H), 3.29 (d, J= 21.4 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H), 1.29 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 158.7, 150.7 (d, ² $J_{P-C} = 8.0$ Hz), 144.3 (d, ⁴ $J_{P-C} = 3.3$ Hz), 119.2 (d, ⁴ $J_{P-C} = 3.2$ Hz), 110.7 (d, ³ $J_{P-C} = 6.4$ Hz), 62.7 (d, ² $J_{P-C} = 6.6$ Hz), 61.0, 27.2 (d, ¹ $J_{P-C} =$ 143.1 Hz), 16.4 (d, ³ $J_{P-C} = 6.0$ Hz), 14.4; ³¹P NMR (162 MHz, CDCl₃): δ 21.6; HRMS: m/z 313.0809 ([M+Na]⁺, C₁₂H₁₉NaO₆P⁺ calcd. 313.0811);

Ethyl *n*-pentyl benzylphosphonate – mixture of diastereoisomers (11). Purified with **A**; yellow oil, 238 mg yield (88 %). ¹H NMR (400 MHz, CDCl₃): δ 7.34-7.25 (m, 5H), 4.05-3.87 (m, 4H), 3.17 (d, J = 21.5 Hz, 2H), 1.61-1.54 (m, 2H), 1.31-1.24 (m, 4H), 1.23 (t, J = 7.0 Hz, 3H), 0.87 (t, J = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 131.8 (d, ² $J_{P-C} = 9.2$ Hz), 129.9 (d, ³ $J_{P-C} = 6.7$ Hz), 128.7 (d, ⁴ $J_{P-C} = 2.9$ Hz), 127.0 (d, ⁵ $J_{P-C} = 3.7$ Hz), 66.2 (d, ² $J_{P-C} = 7.0$ Hz) 62.3 (d, ² $J_{P-C} = 6.6$ Hz), 33.9 (d, ¹ $J_{P-C} = 137.9$ Hz), 30.3 (d, ³ $J_{P-C} = 6.1$ Hz), 27.7, 22.3, 16.5 (d, ³ $J_{P-C} = 6.2$ Hz), 14.1; ³¹P NMR (162 MHz, CDCl₃): δ 26.4; HRMS: *m*/*z* 293.1269 ([M+Na]⁺, C₁₁H₁₇NaO₃P⁺ calcd. 293.1277);

(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl ethyl benzylphosphonate – mixture of diastereoisomers (12). Purified with A; yellow oil, 233 mg yield (74 %). ¹H NMR (400 MHz, CDCl₃): δ 7.32-7.22 (m, 5H), 4.18 (m, 1H), 3.70 and 3.68 (2×t, *J* = 5.6 Hz, 1H), 3.185 and 3.179 (2×d, *J* = 21.8 Hz, 2H), 1.39 (s, 3H), 1.33 (s, 3H), 1.24 (t, *J* =

7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 131.42 and 131.38 (2×d, $J_{P-C} = 9.1$ Hz), 129.94 and 129.92 (2×d, $J_{P-C} = 6.7$ Hz), 128.7 (d, $J_{P-C} = 3.0$ Hz), 127.1 (d, $J_{P-C} = 3.5$ Hz), 109.9, 74.48 and 74.45 (d, $J_{P-C} = 6.8$ Hz), 66.2 (d, $J_{P-C} = 4.8$ Hz), 66.04 and 66.01 (2×d, $J_{P-C} = 6.8$ Hz), 62.55 and 62.50 (2×d, $J_{P-C} = 6.6$ Hz), 33.77 and 33.75 (2×d, $J_{P-C} = 138.3$ Hz), 26.9, 25.41, 25.40, 16.5 (d, $J_{P-C} = 6.0$ Hz); ³¹P NMR (162 MHz, CDCl₃): δ 27.03 and 27.01; HRMS: m/z 337.1167 ([M+Na]⁺, C₁₁H₁₇NaO₃P⁺ calcd. 337.1175);

Cholesteryl ethyl benzylphosphonate – **mixture of diastereoisomers (13).** Purified with **A**; white amorphous solid, 500 mg yield (88 %). ¹H NMR (400 MHz, CDCl₃): δ 7.34-7.20 (m, 5H), 5.34 and 5.26 (2×m, 1H), 4.16 (m, 1H), 4.03-3.94 (m, 2H), 3.14 (d, *J* = 21.7 Hz, 2H), 2.40-0.80 (m, 43H), 0.66 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 139.7 (d, *J*_{P-C} = 3.7 Hz), 132.0 (d, *J*_{P-C} = 9.1 Hz), 129.98 and 129.96 (2×d, *J*_{P-C} = 6.7 Hz), 128.60 and 128.58 (2×d, *J*_{P-C} = 2.4 Hz), 126.94 and 126.91 (2×d, *J*_{P-C} = 3.6 Hz), 122.93 (d, *J*_{P-C} = 4.0 Hz), 76.85 and 76.79 (2×d, *J*_{P-C} = 6.8 Hz), 62.05 and 61.98 (2×d, *J*_{P-C} = 7.2 Hz), 56.8, 56.3, 50.1, 42.43, 40.6 (d, *J*_{P-C} = 3.3 Hz), 40.1 (d, *J*_{P-C} = 4.8 Hz), 39.8, 39.6, 37.08, 37.04, 36.51, 36.49, 36.3, 35.9, 35.1, 33.8, 32.00, 31.96, 31.06, 30.26, 30.23, 29.89, 29.84, 28.35, 28.14, 24.4, 24.0, 23.0, 22.7, 21.2, 19.4, 18.8, 16.53, 16.47, 12.0; ³¹P NMR (162 MHz, CDCl₃): δ 25.52 and 25.48; HRMS: *m*/z 591.3948 ([M+Na]⁺, C₃₆H₅₇NaO₃P⁺ calcd. 591.3938);

5'-*O*-(*tert*-Butyldiphenylsilyl)thymidin-3'-yl 3'-*O*-(dimethoxytrityl)thymidin-5'-yl benzylphosphonate – mixture of diastereoisomers (14). Off-white amorphous solid, 511 mg (88 %). ¹H NMR (400 MHz, CDCl₃): δ 9.54, 9.39, 9.35 (3×s, H3_a, H3_b, 2H), 7.72-6.80 (m, H_{Ar} + H6_a, H6_b, 30H), 6.48-6.26 (m, H1'_a, H1'_b, 2H), 5.02, 4.92 (2×t, H3'_a, *J* = 6.4 Hz, 1H), 4.24-3.44 (m, H3'_b, H4'_a, H4'_b, H5'_a, H5''_a, H5''_b, H5''_b, 2×OCH₃, 13H), 3.28-3.00 (m, PCH₂, 2H), 2.47-1.99 (m, H2'_a, H2''_a, H2''_b, 3H), 1.92,

1.90 (2×s, H5_b, 3H), 1.56, 1.54 (2×s, H5_a, 3H), 1.54 (m, H2"_b, 1H), 1.08, 1.06 (2×s, tB-Si, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 164.0, 163.9, 158.9, 150.6, 150.5, 145.0, 144.9, 136.18, 136.11, 136.05, 136.03, 135.9, 135.6, 135.4, 135.3, 134.9,133.0, 132.9, 132.8, 132.5, 132.13, 132.08, 130.33, 130.26, 130.16, 129.8, 129.75, 129.72, 129.12, 128.89, 128.87, 128.41, 128.33, 128.18, 128.10, 128.06, 127.53, 127.32, 125.4, 113.5, 113.4, 111.70, 111.64, 111.4, 111.3, 111.2, 87.6, 87.5, 87.2, 86.1, 85.9, 85.53, 85.47, 85.3, 84.8, 84.4, 84.3, 84.2, 77.6 (*J*_{P-C} = 6.4 Hz), 77.5 (*J*_{P-C} = 6.3 Hz), 74.1, 73.8, 72.3, 65.6, 64.3, 63.8, 60.5, 55.37, 55.34, 41.1, 39.6, 39.2, 39.1, 33.9 (*J*_{P-C} = 138 Hz), 27.1, 21.5, 21.1, 19.4, 14.3, 12.7, 12.2, 12.05, 11.98; ³¹P NMR (162 MHz, CDCl₃): δ 28.2 and 27.1; HRMS: *m/z* 1183.4261 ([M+Na]⁺, C₆₄H₆₉N₄NaO₁₃PSi⁺ calcd. 1183.4260);

5'-O-(*tert*-Butyldiphenylsilyl)thymidin-3'-yl N⁴-benzoyl-3'-O-

(dimethoxytrityl)deoxycytidine-5'-yl benzylphosphonate mixture of diastereoisomers (15). Off-white amorphous solid, 531 mg (85 %). ¹H NMR (400 MHz, CDCl₃): δ 8.97, 8.91 (2×bs, H3_a and C4NH_b, 2H), 8.08-6.79 (m, H_{Ar}, H6_a, H5_b, H6_b, 36H), 6.47-6.26 (m, H1'_a, H1'_b, 2H), 4.97 and 4.90 (2×t, H3'_a, J = 6.0 and 6.2 Hz, 1H), 4.17 (m, H2'_b, 1H), 4.07-3.62 (m, 10H), 3.51-3.41 (m, H5'_a, 2H), 3.14-2.95 (m, PCH₂, 2H), 2.47 (m, H4'_b, 1H), 2.37-2.05 (2×m, H2'_a, 2H), 1.54, 1.49 (2×s, H5, 3H), 1.49 (m, H2"_b, 1H), 1.09, 1.04 (2×s, tB-Si, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 163.7, 162.4, 158.9, 150.3, 144.94, 144.91, 136.14, 136.12, 136.06, 135.6, 135.4, 135.34, 135.28, 135.08, 135.00, 133.2, 132.9, 132.8, 132.1, 130.36, 130.33, 130.29, 130.24, 129.83, 129.76, 129.0, 128.96, 128.92, 128.43, 128.39, 128.2, 128.1, 127.8, 127.59, 127.56, 127.36, 113.6, 113.4, 111.6, 111.4, 111.24, 88.0, 87.66, 86.28, 86.26, 85.53, 84.47, 85.19, 85.13, 85.03, 84.96, 84.82, 84.6, 84.2, 77.8 (d, $J_{P-C} = 6.0$ Hz), 77.5 (d, $J_{P-C} = 6.3$ Hz), 74.2, 74.1, 72.4, 65.31 (d, $J_{P-C} = 6.3$ Hz), 65.19 (d, $J_{P-C} = 6.4$ Hz), 64.3, 63.83, 63.81, 62.5, 55.40, 55.37, 41.9, 40.9, 39.7, 39.23, 39.17, 34.06 (d,

 $J_{P-C} = 136.4 \text{ Hz}$), 33.99 (d, $J_{P-C} = 138.2 \text{ Hz}$), 27.1, 19.47, 19.44, 12.2, 12.1, 12.0; ³¹P NMR (162 MHz, CDCl₃): δ 28.0 and 27.5; HRMS: m/z 1272.4514 ([M+Na]⁺, C₇₀H₇₂N₅NaO₁₃PSi⁺ calcd. 1272.4526);

5'-O-(*tert*-Butyldiphenylsilyl)thymidin-3'-yl N²-*iso*-butyryl-3'-O-

(dimethoxytrityl)deoxyguanosine-5'-yl benzylphosphonate – mixture of diastereoisomers (16). Off-white amorphous solid, 502 mg (80 %). ¹H NMR (400 MHz, CDCl3): δ 12.10, 12.05 (1H, 2×s, C2NH_b), 10.52, 10.49 (2×s, H3_b, 1H), 9.08, 8.98 (2×s, H3_a, 1H) 7.72-6.75 (m, H_{Ar} + H6_a, H8_b, 30H), 6.43-6.07 (2×dd + m, H1'_a, H1'_b, 2H), 5.03, 4.78 (2×m, H3'_a, 1H), 4.28-3.44 (m, H3'_b, H4'_a, H4'_b, H5'_a, H5"_a, H5'_b, H5''_b, 2×OCH₃, 13H), 3.19-2.95 (m, PCH₂, 2H), 2.70-1.65 (m, H2'_a, H2''_a, H2'_b, H2"_b, (CH₃)₂CH, 5H), 1.59, 1.50 (s, CH_{3a}, 3H), 1.22, 1.18, 1.09, 1.07 (4×d, $(CH_3)_2$ CH, J = 6.4-7.0 Hz, 6H), 1.06, 1.00 (2×s, tB-Si, 9H); ¹³C NMR (100 MHz, CDCl₃): *δ* 179.6, 179.5, 178.6, 171.1, 163.5, 163.4, 158.8, 155.6, 155.4, 155.0, 150.3, 150.2, 147.7, 147.6, 147.5, 147.3, 146.8, 145.0, 144.8, 144.5, 139.7, 139.6, 136.2, 136.1, 136.0, 135.8, 135.7, 135.43, 135.40, 135.1, 135.0, 134.7, 132.4, 132.0, 130.3, 130.2, 130.1, 130.0, 129.5, 129.4, 128.79, 128.72, 128.2, 128.0, 127.9, 127.52, 127.47, 127.4, 127.3, 127.24, 127.17, 127.1, 123.3, 122.9, 113.4 (arom. + C2_a, C2_b, C4_a, C4_b, C5_b, C6_a, C6_b, C8_b, C=O), 111.6, 111.5 (C5_a), 87.7, 87.6, 87.5, 87.3, 87.1, 87.0, 85.8, 85.5, 84.5, 84.4, 84.3 (C1'a, C1'b, C4'a, C4'b, Ar₃C), 78.2, 77.0 (d, C3'a, J = 7.0 Hz, 74.4, 74.3 (C3'_b), 66.1, 66.0, 63.8, 63.6 (C5'_a, C5'_b), 55.3, 55.2 (CH₃O), 39.3, 39.1, 37.8, 37.4, 36.3, 35.7, 35.6 (C2'_a, C2'_b, (CH₃)₂CH), 33.4, 33.0 (2×d, PCH₂, J = 139 Hz), 26.9 ((CH₃)₃CSi), 19.4, 19.3, 19.2, 19.0, 18.9, 18.7, 18.3 ((CH₃)₂CH, (CH₃)₃CSi), 12.0, 11.8 (CH_{3a}); ³¹P NMR (162 MHz, CDCl₃): δ 29.5 and 26.7; HRMS: m/z 1278.4752 ([M+Na]⁺, C₆₈H₇₄N₇NaO₁₃PSi⁺ calcd. 1278.4744);

N⁶-benzoyl-3'-O-5'-O-(tert-Butyldiphenylsilyl)thymidin-3'-yl benzylphosphonate (dimethoxytrityl)deoxyadenosin-5'-vl mixture _ of diastereoisomers (17). Off-white amorphous solid, 516 mg (81 %). ¹H NMR (400 MHz, CDCl₃): δ 9.93, 9.76, 9.62, 9.38 (4×s, H2_b, C6NH_b, 2H), 8.80, 8.77 (2×s, H3_a, 1H): 8.25-6.81 (m, H_{Ar}, H6_a, H8_b, 35H), 6.52-6.17 (m, H1'_a, H1'_b, 2H), 4.93-4.82 (m, H3'a, 1H), 4.45-4.35 (m, H3'b, 1H), 4.13 (m, H4'b, 1H), 3.96 (m, H5'b, 1H), 3.83- $3.72 \text{ (m, H5"}_{b}, 2 \times \text{OCH}_{3}, 7\text{H}), 3.69 \text{ (dd, H5'}_{a}, J = 11.5, 2.5 \text{ Hz}, 1\text{H}), 3.63 \text{ (m, H4'}_{a}, J = 11.5, 2.5 \text{Hz}, 1\text{H}), 3.63 \text{ (m, H4'}_{a}, J = 11.5, 2.5 \text{Hz}, 1\text{H}), 3.63 \text{ (m, H4'}_{a}, J = 11.5, 2.5 \text{Hz}, 1\text{H}), 3.63 \text{ (m, H4'}_{a}, J = 11.5, 2.5 \text{Hz}, 1\text{H}), 3.63 \text{ (m, H4'}_{a}, J = 11.5, 2.5 \text{Hz}, 1\text{H}), 3.63 \text{ (m, H4'}_{a}, J = 11.5, 2.5 \text{Hz}, 1\text{H}), 3.63 \text{ (m, H4'}_{a}, J = 11.5, 2.5 \text{Hz}, 1\text{H}), 3.63 \text{ (m, H4'}_{a}, J = 11.5, 2.5 \text{Hz}, 1\text{H}), 3.63 \text{ (m, H4'}_{a}, J = 11.5, 2.5 \text{Hz}, 1\text{H}), 3.63 \text{ (m, H4'}_{a}, J = 11.5$ 1H), 3.37 (m, H5"_a, J = 11.5, 2.5 Hz, 1H,), 3.14-2.91 (m, PCH₂, 2H), 2.32-1.86 (m, $H2'_{a}, H2''_{b}, H2''_{b}, H2''_{b}, 4H$, 1.42 (m, $CH_{3a}, 3H$), 1.01, 1.00 (2×s, (CH_{3})₃Si, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 171.1, 165.2, 164.0, 164.8, 163.8, 163.6, 158.8, 158.7, 152.6, 152.3, 151.8, 151.6, 150.7, 150.3, 149.9, 149.7, 145.0, 144.8, 144.7, 142.7, 141.7, 141.1, 136.3, 136.2, 135.9, 135.85, 135.81, 135.5, 135.4, 135.1, 134.8, 133.9, 133.5, 133.4, 132.8, 132.7, 132.5, 132.0, 131.9, 130.3, 130.2, 130.1, 130.0, 129.7, 129.6, 128.7, 128.6, 128.5, 128.2, 128.1, 128.0, 127.97, 127.90, 127.3, 127.2, 123.6, 123.4, 113.4 (arom. $+ C2_a, C4_a$), 111.4, 111.3 (C5_a), 87.4 (Ar₃C), 85.9 (d, J = 3.5 Hz), 85.3 (d, J = 6.0 Hz), 84.7 (d, J = 7.4 Hz), 84.5 (d, J = 7.4 Hz) (C4'_b, C4'_b), 84.8, 84.3, 84.1, 83.9 (C1'_a, C1'_b), ~77.5 (C3'_a), 74.1, 73.8 (C3'_b), 65.6 (d, J = 7.6 Hz), 65.0 (d, J= 7.2 Hz (C5[']_b), 63.6, 63.5 (C5[']_a), 55.2 (CH₃O), 39.6, 39.4, 39.0 (d, J = 5.6 Hz), 38.8 $(C2'_{a}, C2'_{b})$, 33.7, 33.5 $(2 \times d, PCH_2, J = 137 \text{ Hz})$, 26.9 $((CH_3)_3 \text{CSi})$, 19.25, 19.23 $((CH_3)_3CSi)$, 11.7 (CH_{3a}) ; ³¹P NMR (162 MHz, CDCl₃): δ 28.1 and 27.3; HRMS: m/z1296.4626 ([M+Na]⁺, C₇₁H₇₂N₇NaO₁₂PSi⁺ calcd. 1296.4638);

Diethyl benzylphosphonothioate (18). Colorless oil, 193 mg yield (79 %). ¹H NMR (400 MHz, CDCl₃): δ 7.33-7.23 (m, 5H), 4.10-3.96 (m, 4H), 3.36 (d, J = 19.0 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 131.7 (d, J_{P-C} = 8.7 Hz), 130. 3 (d, J_{P-C} = 6.5 Hz), 128.4 (d, J_{P-C} = 3.6 Hz), 127.2 (d, J_{P-C} = 4.4 Hz), 63.0 (d, J_{P} .

C = 7.1 Hz), 42.7 (d, J{P-C} = 108.3 Hz), 16.2 (d, J_{P-C} = 6.9 Hz); ³¹P NMR (162 MHz, CDCl₃): δ 93.5; HRMS: m/z 267.0586 ([M+Na]⁺, C₁₁H₁₇NaO₂PS⁺ calcd. 267.0579);

5'-O-(tert-Butyldiphenylsilyl)thymidin-3'-yl ethyl benzylphosphonothioate – mixture of diastereoisomers (19). White amorphous solid, 282 mg yield (83 %). ¹H NMR (400 MHz, CDCl₃): δ 8.80 (bs, H3, 1H), 7.67-7.60 (m, H_{Ar}, 4H), 7.49-7.16 (m, H_{Ar} and H6, 12H), 6.40 (m, H1', 1H), 5.33 and 5.15 (2×m, H3', 1H), 4.13 (m, H4', 0.5H), 4.12-3.96 (m, POC H_2 , 2H), 3.91-3.86 (m, H5', 1H), 3.79 (dd, H5', J = 11.5, 1.8 Hz, 0.5H), 3.72 (m, H4', 0.5H), 3.67 (dd, H5', J = 11.5, 2.1 Hz, 0.5H), 3.41 and 3.38 (2×d, PCH₂, J = 19.2 Hz, 2H), 2.45 (dd, H2', J = 13.8, 5.1 Hz, 0.5H), 2.24-2.15 (m, H2', 1H), 2.05 (m, H2', 0.5H), 1.59 and 1.57 (2×s, H5, 3H), 1.28 and 1.18 (2×t, POCH₂CH₃, J = 7.1 Hz, 3H), 1.06 and 1.05 (2×s, tB-Si, 9H); ¹³C NMR (100 MHz, CDCl₃): *δ* 163.70, 163.67, 150.47, 135.77, 135.77, 135.3, 135.07, 135.04, 133.0, 132.9, 132.0, 131.9, 130.90 and 130.87 ($2 \times d$, $J_{P-C} = 8.3$ Hz), 130.40 and 130.37 ($2 \times d$, $J_{P-C} = 6.4$ Hz), 130.32, 130.2, 128.63, and 128.5 (2×d, $J_{P-C} = 3.8$ Hz), 128.2, 128.1, 127.6 and 127.5 (2×d, $J_{P-C} = 4.4$ Hz), 111.67, 111.63, 86.30, 86.28, 86.01, 85.96, 84.54, 84.48, 77.9 and 77.2 (2×d, J_{P-C} = 6.7 Hz), 63.90, 63.84, 63.3 and 63.0 (2×d, J_{P-C} $_{\rm C}$ = 7.4 Hz), 42.9 (d, $J_{\rm P-C}$ = 107.5 Hz), 42.6 (d, $J_{\rm P-C}$ = 108.3 Hz), 39.80, 39.76, 39.28, 39.21, 31.4, 27.1, 19.49, 19.46, 16.31 and 16.16 ($2 \times d$, $J_{P-C} = 7.2$ Hz), 12.15, 12.09; ³¹P NMR (162 MHz, CDCl₃): δ 95.1 and 94.5 ; HRMS: *m/z* 701.2260 ([M+Na]⁺, $C_{35}H_{43}N_2NaO_6PSSi^+$ calcd. 701.2241);

Benzyl-(5-(diphenylphosphino)-9,9-dimethyl-9H-xanthen-4-

yl)diphenylphosphonium bromide.

Xantphos (0.2 mmol, 116 mg) and benzyl bromide (0.6 mmol, 72 μ L) was refluxed in THF (3 mL) overnight. After cooling (0 °C) the reaction mixture, the precipitated crystals were filtered off and washed with cold diethyl ether to obtain the pure compound in 72 % (108 mg) yield after evaporation.

¹H NMR (400 MHz, CDCl3): δ 8.01 and 7.99 (2×s, 1H), 7.68-7.60 (m, 2H), 7.54-7.44 (m, 9H), 7.36-7.26 (m, 2H), 7.23-7.15 (m, 7H), 7.12-7.15 (m, 7H), 7.12-7.05 (m, 5H), 6.96-6.88 (m, 4H), 6.64 (m, 1H), 5.23 (dd, ²*J*_{P-H} = 16 Hz and ⁸*J*_{P-H} = 4 Hz), 1.75 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 153.5, 151.0, 151.4, 135.7, 135.6, 135.5, 135.4, 135.0, 134.7, 134.2, 134.1, 133.5, 133.3, 132.9, 131.0, 130.1, 130.0, 129.6, 128.9, 128.8, 128.7, 128.5, 127.8, 125.6, 125.5, 125.3, 124.4, 124.2, 118.1, 117.3, 104.8, 104.0, 34.7, 32.4, 30.8 (dd, *J*_{P-C} = 46.7, 14.6 Hz); ³¹P NMR (162 MHz, CDCl₃): δ 23.1 and -21.3; HRMS: *m/z* 771.1560 ([M+Na]⁺, C₄₆H₃₉BrNaOP₂⁺ calcd. 771,1552);

































Supplementary Material (ESI) for New Journal of Chemistry This journal is © The Royal Society of Chemistry and The Centre National de la Recherche Scientifique, 2009























Supplementary Material (ESI) for New Journal of Chemistry This journal is © The Royal Society of Chemistry and The Centre National de la Recherche Scientifique, 2009



Figure S1. Comparison between 3 mol% $Pd(OAc)_2 + 6$ mol% Xantphos and 1.5 mol% Pd₂dba₃ (CHCl₃) + 3 mol% Xantphos in coupling of Bn-Cl with diethyl Hphosphonate under standard reaction conditions.



Figure S2. Alkylation of different phosphine ligands with benzyl bromide, in THF at 60 °C (0.10 mmol bidentate ligands or 0.20 mmol triphenylphosphine, 1.0 mmol benzyl bromide, 5 mL THF).



Triphenylphosphine (TPP)

Supplementary Material (ESI) for New Journal of Chemistry This journal is © The Royal Society of Chemistry and The Centre National de la Recherche Scientifique, 2009

DPEphos $t_{1/2} = 30.5$ min Xantphos $t_{1/2} = 91.2$ min Triphenylphosphine $t_{1/2} = 100.5$ min



Figure S3. Comparison of xantphos alkylation with benzyl bromide, in presence and absence of Pd₂dba₃(CHCl₃), in THF at 60 °C (0.10 mmol xantphos, 1.0 mmol benzyl bromide, none or 0.05 mmol Pd Pd₂dba₃(CHCl₃), 5 mL THF).



Figure S4. ³¹P NMR spectra showing the oxidative additon of equimolar amounts of benzyl bromide to $Pd_2(dba)_3(CHCl_3)$]/Xantphos (1:2 mol ratio), followed by the reaction of added diethyl H-phosphonothioate (5 equiv.) and *N*,*N*-diisopropylethylamine (5 equiv.).